Research, engineered into a diagnosis
Temnography® began as a research programme focused on developing original, patentable technologies at the intersection of electronics, software and diagnostic imaging. This work led to the creation of Computerized Tissue Temnography, along with the patents, technical know-how and scientific expertise that underpin the technology.
TEMNOGRAPHY was established as a company in 2023 to bring this technological heritage into a new phase of development, acquiring the original patents, know-how and accumulated expertise and accelerating the transition from research and prototypes to clinically validated, market-ready medical devices.
Since then, TEMNOGRAPHY has driven the clinical development, regulatory activities, technical certification and clinical evidence generation required to support the commercialisation and international expansion of the TES HT family of devices. Today, the company is focused on bringing Temnography® technology into clinical practice while continuing to develop its broader technological and clinical potential.
Our Journey
2023
TEMNOGRAPHY acquires the technology and patents
Development of a novel low-power radiofrequency approach for the non-invasive assessment of intracranial abnormalities.
2023
First clinical feasibility studies
Initial clinical investigations generated the first human evidence to support the continued development of TES HT.
1 / 8
2023
TEMNOGRAPHY acquires the technology and patents
Development of a novel low-power radiofrequency approach for the non-invasive assessment of intracranial abnormalities.
2023
First clinical feasibility studies
Initial clinical investigations generated the first human evidence to support the continued development of TES HT.
2023
New GMDN category established
A dedicated GMDN term was established for Temnography® technology, “Radio-frequency intracranial haemorrhage detector”, reflecting its distinctive technological approach.
2023
TES HT receives CE marking
TES HT reaches its first major European regulatory milestone.
2024
TESCO prospective clinical programme launched
The TESCO clinical programme was launched to prospectively evaluate TES HT in Emergency Department patients with mild head trauma or acute neurological symptoms, as part of a multicentre clinical development programme.
2025
IECEE CB Test Certificates obtained
The TES HT family obtained IECEE CB Test Certificates, issued by TÜV Rheinland, covering the applicable IEC 60601 requirements for medical electrical equipment, including IEC 60601-1, IEC 60601-1-6 and IEC 60601-1-2.
2026
First large prospective clinical validation results published
Interim results from the prospective TESCO clinical study were published in BMC Emergency Medicine and indexed in PubMed, marking a major milestone in the clinical validation of TES HT.
2026 onward
Expanding clinical and international development
Continued clinical development, generation of additional evidence and regulatory progress will support the broader adoption of TES HT and the development of new Temnography® devices.
Leadership Team
Bruno Basile
Fulvio Scognamiglio
Fabrizio Alfieri
Pasquale Cuccaro, Ph.D.
Giuseppe Porcelli